As of 2025-07-06, the Intrinsic Value of Monopar Therapeutics Inc (MNPR) is -13.54 USD. This MNPR valuation is based on the model Peter Lynch Fair Value. With the current market price of 36.25 USD, the upside of Monopar Therapeutics Inc is -137.36%.
Based on its market price of 36.25 USD and our intrinsic valuation, Monopar Therapeutics Inc (MNPR) is overvalued by 137.36%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -13.54 - -13.54 | -13.54 | -137.36% |
| P/E | (2.98) - (35.48) | (19.64) | -154.2% |
| DDM - Stable | (18.86) - (54.51) | (36.69) | -201.2% |
| DDM - Multi | (14.00) - (32.49) | (19.68) | -154.3% |
| Market Cap (mil) | 221.85 |
| Beta | 1.93 |
| Outstanding shares (mil) | 6.12 |
| Enterprise Value (mil) | 182.14 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.26% |
| Cost of Debt | 5.00% |
| WACC | 7.47% |